Literature DB >> 18805651

Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.

John W Nelson1, A Paiman Ghafoori, Christopher G Willett, Douglas S Tyler, Theodore N Pappas, Bryan M Clary, Herbert I Hurwitz, Johanna C Bendell, Michael A Morse, Robert W Clough, Brian G Czito.   

Abstract

PURPOSE: Extrahepatic cholangiocarcinoma is a rare malignancy. Despite radical resection, survival remains poor, with high rates of local and distant failure. To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy. METHODS AND MATERIALS: A total of 45 patients (13 with proximal and 32 with distal disease) underwent resection plus radiotherapy (median dose, 50.4 Gy). All but 1 patient received concurrent fluoropyrimidine-based chemotherapy. The median follow-up was 30 months for all patients and 40 months for survivors.
RESULTS: Of the 45 patients, 33 underwent adjuvant radiotherapy, and 12 were treated neoadjuvantly. The 5-year actuarial overall survival, disease-free survival, metastasis-free survival, and locoregional control rates were 33%, 37%, 42%, and 78%, respectively. The median survival was 34 months. No patient died perioperatively. Patient age </=60 years and perineural involvement adversely affected survival on univariate analysis. Patients undergoing R0 resection had a significantly improved rate of local control but no survival advantage. Despite having more advanced disease at presentation, patients treated neoadjuvantly had a longer survival (5-year survival 53% vs. 23%, p = 0.16) and similar rates of Grade 2-3 surgical morbidity (16% vs. 33%, p = 0.24) compared with those treated in the postoperative setting.
CONCLUSION: These study results suggest a possible local control benefit from chemoradiotherapy combined with surgery in patients with advanced, resected biliary cancer. Furthermore, our results suggest that a treatment strategy that includes preoperative chemoradiotherapy might result in improved tumor resectability with similar surgical morbidity compared with patients treated postoperatively, as well as potentially improved survival outcomes. Distant failure remains a significant failure pattern, suggesting the need for more effective systemic therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805651      PMCID: PMC4142576          DOI: 10.1016/j.ijrobp.2008.07.008

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma.

Authors:  K M McMasters; T M Tuttle; S D Leach; T Rich; K R Cleary; D B Evans; S A Curley
Journal:  Am J Surg       Date:  1997-12       Impact factor: 2.565

Review 3.  The role of radiation therapy in cancer of the extra-hepatic biliary system: an analysis of thirteen patients and a review of the literature of the effectiveness of surgery, chemotherapy and radiotherapy.

Authors:  G Kopelson; L Harisiadis; P Tretter; C H Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 Sep-Oct       Impact factor: 7.038

4.  Patterns of failure after curative surgery for extra-hepatic biliary tract carcinoma: implications for adjuvant therapy.

Authors:  G Kopelson; J Galdabini; A L Warshaw; L L Gunderson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-03       Impact factor: 7.038

Review 5.  Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.

Authors:  F R Spitz; J L Abbruzzese; J E Lee; P W Pisters; A M Lowy; C J Fenoglio; K R Cleary; N A Janjan; M S Goswitz; T A Rich; D B Evans
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

6.  Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection.

Authors:  Seung-Woo Park; Young Soo Park; Jae Bock Chung; Jin Kyung Kang; Kyung Sik Kim; Jin Sup Choi; Woo-Jung Lee; Byong Ro Kim; Si Young Song
Journal:  Hepatogastroenterology       Date:  2004 Nov-Dec

7.  Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy.

Authors:  Steve M M de Castro; Koert F D Kuhlmann; N Tjarda van Heek; Olivier R C Busch; G Johan Offerhaus; Thomas M van Gulik; Hugo Obertop; Dirk J Gouma
Journal:  J Gastrointest Surg       Date:  2004-11       Impact factor: 3.452

8.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

Authors:  M H Kalser; S S Ellenberg
Journal:  Arch Surg       Date:  1985-08

Review 9.  Gallbladder and biliary tract carcinoma: A comprehensive update, Part 2.

Authors:  William P Daines; Vandana Rajagopalan; Michael L Grossbard; Peter Kozuch
Journal:  Oncology (Williston Park)       Date:  2004-07       Impact factor: 2.990

10.  Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.

Authors:  C G Moertel; S Frytak; R G Hahn; M J O'Connell; R J Reitemeier; J Rubin; A J Schutt; L H Weiland; D S Childs; M A Holbrook; P T Lavin; E Livstone; H Spiro; A Knowlton; M Kalser; J Barkin; H Lessner; R Mann-Kaplan; K Ramming; H O Douglas; P Thomas; H Nave; J Bateman; J Lokich; J Brooks; J Chaffey; J M Corson; N Zamcheck; J W Novak
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

View more
  45 in total

1.  Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.

Authors:  Evan S Glazer; Ping Liu; Eddie K Abdalla; Jean-Nicolas Vauthey; Steven A Curley
Journal:  J Gastrointest Surg       Date:  2012-07-10       Impact factor: 3.452

2.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

3.  Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis.

Authors:  Clifton D Fuller; Samuel J Wang; Mehee Choi; Brian G Czito; John Cornell; Tania M Welzel; Katherine A McGlynn; Join Y Luh; Charles R Thomas
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

Review 4.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

5.  A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.

Authors:  Evan J Walker; Jeffry P Simko; Eric K Nakakura; Andrew H Ko
Journal:  J Gastrointest Oncol       Date:  2014-12

6.  Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma.

Authors:  Angela Y Jia; Jian-Xiong Wu; Yu-Ting Zhao; Ye-Xiong Li; Zhi Wang; Wei-Qi Rong; Li-Ming Wang; Jing Jin; Shu-Lian Wang; Yong-Wen Song; Yue-Ping Liu; Hua Ren; Hui Fang; Wen-Qing Wang; Xin-Fan Liu; Zi-Hao Yu; Wei-Hu Wang
Journal:  J Gastrointest Oncol       Date:  2015-04

7.  Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma.

Authors:  Yeona Cho; Tae Hyung Kim; Jinsil Seong
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

Review 8.  Current state of nonsurgical therapies for cholangiocarcinoma.

Authors:  Volker Brass; Jan B Kuhlmann; Hubert E Blum
Journal:  Hepat Oncol       Date:  2013-12-20

9.  Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.

Authors:  Ka Wing Ma; Tan To Cheung; Wong Hoi She; Kenneth Siu Ho Chok; Albert Chi Yan Chan; Wing Chiu Dai; Wan Hang Chiu; Chung Mau Lo
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

Review 10.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.